m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00202)
Name
Benzyl-(9-isopropyl-9H-purin-6-yl)-amine
Synonyms
CHEMBL85015; 111853-20-4; 9H-Purin-6-amine, 9-(1-methylethyl)-N-(phenylmethyl)-; purine deriv. 9; ACMC-20mewm; SCHEMBL754120; BDBM10641; CTK0D3360; DTXSID10444118; 6-(benzylamino)-9-isopropylpurine; ZINC13538226; AKOS030562149; 6-(Benzylamino)-9-isopropyl-9H-purine; N-benzyl-9-isopropyl-9H-purin-6-amine
    Click to Show/Hide
Status
Investigative
Structure
Formula
C15H17N5
InChI
1S/C15H17N5/c1-11(2)20-10-19-13-14(17-9-18-15(13)20)16-8-12-6-4-3-5-7-12/h3-7,9-11H,8H2,1-2H3,(H,16,17,18)
InChIKey
JBLZWJCKPDQCNX-UHFFFAOYSA-N
PubChem CID
10730551
TTD Drug ID
D0M5PI
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Cyclin-dependent kinase 2 (CDK2)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Benzyl-(9-isopropyl-9H-purin-6-yl)-amine. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Benzyl-(9-isopropyl-9H-purin-6-yl)-amine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). [1], [2]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Benzyl-(9-isopropyl-9H-purin-6-yl)-amine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Benzyl-(9-isopropyl-9H-purin-6-yl)-amine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). [2], [3]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Benzyl-(9-isopropyl-9H-purin-6-yl)-amine. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Benzyl-(9-isopropyl-9H-purin-6-yl)-amine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). [1], [2]
References
Ref 1 FTO regulates adipogenesis by controlling cell cycle progression via m(6)A-YTHDF2 dependent mechanism. Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Oct;1863(10):1323-1330. doi: 10.1016/j.bbalip.2018.08.008. Epub 2018 Aug 13.
Ref 2 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Ref 3 YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. Nat Commun. 2019 Oct 25;10(1):4892. doi: 10.1038/s41467-019-12801-6.